Checked
Zeo ScientifiX, Inc.
OTC: ZEOX · Biological Products, (No Diagnostic Substances) · Davie, FL
- Revenue
- $5.2M
- +12.5% vs. prior year
- Net income
- -$5.52M
- -106.2% net margin
- Total assets
- $1.53M
- Diluted EPS
- -$0.86
Company details
As reported to the SEC
- SEC CIK
- 1557376
- Stock
- OTC: ZEOX
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- Headquarters
- 3321 College Avenue, Suite 246, Davie, FL 33314
- Incorporated in
- Nevada
- Fiscal year end (SEC record)
- June 30
- Filer status
- Non-accelerated filer, Smaller reporting company
- Phone
- (888) 963-7881
- Employer ID (EIN)
- 47-4180540
- Last annual report
- 10/13/2026
- Last quarterly report
- 06/15/2026
Formerly: Organicell Regenerative Medicine, Inc. (until 01/29/2024); Biotech Products Services & Research, Inc. (until 06/15/2018); BESPOKE TRICYCLES INC (until 09/14/2015)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 10/31/2025 | 10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 |
|---|---|---|---|---|---|
| Revenue | $5.2M | $4.62M | $4.56M | $6.49M | $5.6M |
| Gross profit | $4.27M | $3.78M | $4.05M | $5.74M | $5.05M |
| Operating income | -$5.39M | -$5.32M | -$6.77M | -$8.84M | -$12.74M |
| Net income | -$5.52M | -$4.71M | -$6.99M | -$8.9M | -$12.76M |
| Diluted earnings per share | -$0.86 | -$0.74 | -$0.99 | -$1.56 | -$0.01 |
| Research and development | $100K | $164K | $922.7K | $791.3K | $1.12M |
| Total assets | $1.53M | $1.64M | $2.78M | $6.2M | $1.93M |
| Total liabilities | $2.95M | $3.3M | $4.02M | $4.31M | $4.6M |
| Shareholders' equity | -$1.42M | -$1.65M | -$1.24M | $1.89M | -$2.67M |
| Cash and cash equivalents | $221K | $657K | $1.76M | $3.75M | $108.6K |
| Cash from operations | -$718K | -$1.45M | -$2.2M | -$3.17M | -$2.68M |
| Capital expenditures | $23K | Not reported | $26K | $824.7K | $424.7K |
Recent filings
130 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
| Form | Filed | Period |
|---|---|---|
| 8-KMaterial agreement | 10/26/2026 | 10/26/2026 |
| 10-KTTransition report | 10/13/2026 | 06/30/2026 |
| NT 10-KNotice of late annual report | 09/28/2026 | 06/30/2026 |
| 8-KBylaws or fiscal year change | 09/15/2026 | 09/10/2026 |
| 8-KOther events | 09/15/2026 | 09/15/2026 |
| NT 10-QNotice of late quarterly report | 09/14/2026 | 07/31/2026 |
| 8-KOther events | 09/01/2026 | 09/01/2026 |
| 8-KOther events | 08/04/2026 | 08/04/2026 |
| SCHEDULE 13D/AOwnership report (5% holder, active, amended) | 07/24/2026 | None |
| SCHEDULE 13D/AOwnership report (5% holder, active, amended) | 07/24/2026 | None |
| SCHEDULE 13G/AOwnership report (5% holder, passive, amended) | 07/24/2026 | None |
| S-8Registration of employee stock plan shares | 07/24/2026 | None |
| 8-KOther events | 07/21/2026 | 07/21/2026 |
| 8-KResults of operations, Regulation FD disclosure | 07/08/2026 | 07/08/2026 |
| 8-KOther events | 07/01/2026 | 07/01/2026 |
| 8-KOther events | 06/16/2026 | 06/16/2026 |
| 10-QQuarterly report | 06/15/2026 | 04/30/2026 |
| 8-KDirector or officer change | 06/12/2026 | 06/10/2026 |
| 8-KOther events | 06/09/2026 | 06/09/2026 |
| 8-KOther events | 05/27/2026 | 05/27/2026 |
8 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Zeo ScientifiX, Inc. in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other biological products, (no diagnostic substances)
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Amgen IncAMGN | Thousand Oaks, CA | $36.75B | $7.71B |
| Gilead Sciences, Inc.GILD | Foster City, CA | $29.44B | $8.51B |
| Biogen Inc.BIIB | Cambridge, MA | $9.89B | $1.29B |
| Neurocrine Biosciences IncNBIX | San Diego, CA | $2.86B | $478.6M |
| Exelixis, Inc.EXEL | Alameda, CA | $2.32B | $782.6M |
| Qiagen N.V.QGEN | Pl Venlo, Netherlands | $2.09B | $424.9M |
| Moderna, Inc.MRNA | Cambridge, MA | $1.94B | -$2.82B |
| Halozyme Therapeutics, Inc.HALO | San Diego, CA | $1.4B | $316.9M |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Zeo ScientifiX, Inc.'s CIK number?
- Zeo ScientifiX, Inc.'s SEC Central Index Key (CIK) is 1557376.
- What is Zeo ScientifiX, Inc.'s stock ticker?
- Zeo ScientifiX, Inc. trades as OTC: ZEOX.
- What was Zeo ScientifiX, Inc.'s revenue?
- Zeo ScientifiX, Inc. reported revenue of $5.2M for the fiscal year ended Oct 31, 2025, +12.5% from the year before.
- When does Zeo ScientifiX, Inc.'s fiscal year end?
- Zeo ScientifiX, Inc.'s fiscal year end on file with the SEC is June 30; its most recent fiscal year ended Oct 31, 2025.
- Where is Zeo ScientifiX, Inc. headquartered?
- Zeo ScientifiX, Inc.'s principal executive office on file with the SEC is in Davie, FL.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026